Hostname: page-component-848d4c4894-xm8r8 Total loading time: 0 Render date: 2024-07-05T08:37:23.606Z Has data issue: false hasContentIssue false
  • English
  • Français

Angioedema and Maculopapular Eruptions Associated with Carbamazepine Administration

Published online by Cambridge University Press:  07 November 2014

Alby Elias ,
Subramoniam Madhusoodanan ,
David Pudukkadan  and
James T. Antony
Get access Rights & Permissions [Opens in a new window]

Abstract

Cutaneous rashes and eruptions can be caused by many medications, including carbamazepine. The presentation can be varied depending on severity. Cutaneous eruptions occur in 3% of individuals administered carbamazepine. Angioedema, a rare side effect of carbamazepine, involves vascular leakage in dermis and subcutis mediated by immunoglobulin E and/or bradykinins. Angioedema is more common in females and in the third decade of life. We report the case of a 27-year-old Indian woman who developed maculopapular rash and angioedema secondary to carbamazepine administration. The patient responded successfully to withdrawal of the drug and treatment with antihistamines. Due to the potentially life-threatening complications of this condition and the increasing use of anticonvulsants in the treatment of mood disorders, psychiatrists must be aware of the diagnosis and treatment of this condition.

Type
Case Report
Information
CNS Spectrums , Volume 11 , Issue 5 , May 2006 , pp. 352 - 354
Copyright
Copyright © Cambridge University Press 2006

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Bigby, M. Rates of cutaneous reactions to drugs. Arch Dermatol. 2001;137:765–770.Google Scholar
2.Bigby, M, Jick, S, Jick, H, Arndt, K. Drug-induced cutaneous reactions. A report from the Boston Collaborative Drug Surveillance Program on 15,438 consecutive inpatients, 1975 to 1982. JAMA. 1986;256:3358–3363.CrossRefGoogle Scholar
3.Hunziker, T, Kunzi, UP, Braunschweig, S, Zehnder, D, Hoigne, R. Comprehensive hospital drug monitoring (CHDM): adverse skin reactions, a 20 year survey. Allergy. 1997;52:388–393.Google Scholar
4.Swanbeck, G, Dahlberg, E. Cutaneous drug reactions. An attempt to quantitative estimation. Arch Dermatol Res. 1992;284:215–218.Google Scholar
5.Roujeau, JC, Stern, RS. Severe adverse cutaneous reactions to drugs. N Engl J Med. 1994;331:1272–1285.Google Scholar
6. Special Report. Recognition and early warning signs of severe drug-induced cutaneous adverse reactions. Sponsored by The John Hopkins University School of Medicine. Date of original release: March 2005.Google Scholar
7.Syn, WK, Naisbitt, DJ, Holt, AP, et al.Carbamazepine-induced acute liver failure as part of the DRESS syndrome. Int J Clin Pract 2005;59:988–991.Google Scholar
8.Kaneko, K, Igarashi, J, Suzuki, Y, Niijima, S, Ishimoto, K, Yabuta, K. Carbamazepine-induced thrombocytopenia and leucopenia complicated by Henoch-Schonlein purpura symptoms. Eur J Pediatr. 1993;152:769–770.CrossRefGoogle ScholarPubMed
9.Harmon, RR. Carbamazepine (Tegretol) drug eruptions. Br J Dermatol. 1967;79:500–501.Google Scholar
10.Roberts, DL, Marks, R. Skin reactions to carbamazepine. Arch Dermatol. 1981;117:273–275.Google Scholar
11.Wintroub, BU, Stern, RS. Cutaneous drug reactions. In: Fauci, AS, Braunwald, E, Isselbacher, K, et al. eds. Harrison's Principles of Internal Medicine. 14th ed. New York, NY: McGraw-Hill: 1998:304–310.Google Scholar
12.Dodds, N, Sinert, R. Angioedema. Emedicine Web site. Available at: http://www.emedicine.com/emerg/topic32.htm. Accessed November 13, 2005.Google Scholar
13.Tennis, P, Stern, RS. Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: a record linkage study. Neurology. 1997;49:542–546.Google Scholar